Skip to main content

Table 4 Risk of ovarian cancer recurrence and CA-125 serum concentration changes 3 and 6 months after therapy in subgroups of patients. NACT-Neoadjuvant chemotherapy

From: Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer

Subgroups of patients Risk of ovarian cancer recurrence - HR (p)
CA-125 changes 3 months
after therapy [U/ml]
CA-125 changes 6 months
after therapy [U/ml]
< 0 0–5 > 5 < 0 0–5 > 5
FIGO 1&2 (n = 52) 1.00 0.97 (p = 0.97) 6.95 (p = 0.085) 1.00 1.57 (p = 0.516) 4.71 (p = 0.09)
FIGO 3&4 (n = 116) 1.00 1.42 (p = 0.145) 6.65 (p < 0.0001) 1.00 1.51 (p = 0.11) 6.33 (p < 0.0001)
Grade 2&3 (n = 152) 1.00 1.28 (p = 0.2885) 7.07 (p < 0.0001) 1.00 1.28 (p = 0.3388) 4.99 (p < 0.0001)
Serous (n = 124) 1.00 1.34 (p = 0.2247) 8.53 (p < 0.0001) 1.00 1.32 (p < 0.2955) 5.17 (p < 0.0001)
NACT
(n = 26)
1.00 1.71 (p = 0.34) 4975 (p = 0.99) 1.00 1.22 (p = 0.698) 2.83 (p = 0.11)
Bevacizumab (n = 32) 1.00 1.62 (p = 0.29) 1.00 1.48 (p = 0.383) 10.1 (p < 0.008)
Optimal cytoreduction (< 1 cm) (n = 145) 1.00 1.34 (p = 0.4) 6.93 (p < 0.014) 1.00 1.64 (p = 0.179) 7.24 (p < 0.0001)